Level D· Scientific groundwork from lab and animal studiesNarrative ReviewPubMed

Mesenchymal and Pluripotent Stem Cell-Based Strategies for Cardiac Regeneration: Mechanisms, Challenges, and Future Directions.

Lei W., Wang X., Cai J., Pan L.

Narrative Review on Cardiovascular Disease, Immune Modulation, published in Biotechnol J (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Biotechnol J (2025)
Country
Germany
Reported sample size
—
Source database
PubMed
PMID
41211779
DOI
10.1002/biot.70152

Abstract (original English)

Cardiovascular diseases (CVDs) remain the predominant cause of morbidity and mortality worldwide, with limited curative treatment options for advanced heart failure (HF). While pharmacological and surgical interventions have improved survival, they often fail to regenerate damaged myocardial tissue. Mesenchymal stem cells (MSCs) have emerged as a promising therapeutic modality in regenerative medicine, particularly for cardiac repair. This review highlights the role of MSCs in addressing the unmet clinical need for myocardial regeneration, focusing on their biological characteristics, mechanisms of action, and therapeutic applications in various CVDs. MSCs, derived from bone marrow or adipose tissue, exhibit immunomodulatory, anti-fibrotic, and pro-angiogenic properties that facilitate cardiac tissue repair. Their ability to be used in an allogeneic, off-the-shelf format offers practical advantages for large-scale clinical use. However, several challenges, including poor survival post-transplantation, inter-source variability, and complex interactions with the ischemic microenvironment, must be addressed to maximize therapeutic efficacy. Emerging technologies such as gene editing, exosome-based delivery, tissue engineering, and 3D bioprinting offer promising strategies to enhance MSC therapy. This review concludes by outlining future directions for standardization, clinical tra

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansMesenchymal Stem CellsRegenerative MedicineMesenchymal Stem Cell TransplantationTissue EngineeringRegenerationAnimalsPluripotent Stem CellsCardiovascular Diseases

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research